{"id":665280,"date":"2023-08-28T14:54:01","date_gmt":"2023-08-28T14:54:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=665280"},"modified":"2023-08-28T14:54:01","modified_gmt":"2023-08-28T14:54:01","slug":"huntingtons-disease-pipeline-and-clinical-trials-assessment-2023-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-sangamo-therapeutics-spark-therapeutics-chong-kun-dang-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/huntingtons-disease-pipeline-and-clinical-trials-assessment-2023-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-sangamo-therapeutics-spark-therapeutics-chong-kun-dang-pharma_665280.html","title":{"rendered":"Huntington\u2019s Disease Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Sangamo Therapeutics, Spark therapeutics, Chong Kun Dang Pharma"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1693115855.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Huntington&rsquo;s Disease Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Sangamo Therapeutics, Spark therapeutics, Chong Kun Dang Pharma\" src=\"https:\/\/www.abnewswire.com\/uploads\/1693115855.jpeg\" alt=\"Huntington&rsquo;s Disease Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Sangamo Therapeutics, Spark therapeutics, Chong Kun Dang Pharma\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">(Las Vegas, Nevada, United States)  As per DelveInsight\u2019s assessment, globally, Huntington\u2019s Disease pipeline constitutes 50+ key companies continuously working towards developing 50+ Huntington\u2019s Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.<\/div>\n<p style=\"text-align: justify;\">The Huntington&rsquo;s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/huntingtons-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Huntington&rsquo;s Disease Pipeline Insight, 2023<\/a>&#8220;<\/strong> report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Huntington&rsquo;s Disease Market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key takeaways from the Huntington&rsquo;s Disease Pipeline Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Companies across the globe are diligently working toward developing novel Huntington&rsquo;s Disease treatment therapies with a considerable amount of success over the years.&nbsp;<\/li>\n<li>Huntington&rsquo;s Disease companies working in the treatment market are <strong>Sangamo Therapeutics, Spark therapeutics, Chong Kun Dang Pharmaceutical, Neuvivo, UniQure Biopharma, Wave Life Sciences, Novartis, Sage Therapeutics, Annexon, Neurocrine Biosciences, Prilenia Therapeutics,<\/strong> and others, are developing therapies for the Huntington&rsquo;s Disease treatment&nbsp;<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Emerging Huntington&rsquo;s Disease therapies in the different phases of clinical trials are- <strong>TAK-686, Huntington&rsquo;s Disease therapy, CKD-504, NP 001, rAAV5-miHTT, WVE003, Branaplam, SAGE-718, ANX005, Valbenazine, Pridopidine,<\/strong> and others are expected to have a significant impact on the Huntington&rsquo;s Disease market in the coming years.&nbsp;&nbsp;&nbsp;<\/li>\n<li><strong>In August 2022, In order to undertake a Phase I\/II trial<\/strong> for its innovative Huntington&#8217;s Disease (HD) gene treatment, BV-101, through its subsidiary BrainVectis in France, Asklepios BioPharmaceutical, a fully owned and independently run subsidiary of Bayer AG, got approval. The National Agency for Safety of Medicines and Health Products (ANSM), the nation&#8217;s regulatory drug agency, has granted the corporation permission to start seeking volunteers after the relevant Ethics Committee approved the trial protocol.<\/li>\n<li><strong>In March 2022, The PIVOT-HD Phase II<\/strong> clinical trial investigating PTC518 in patients with Huntington&#8217;s disease (HD) has begun, according to PTC Therapeutics. An international trial called PIVOT-HD is beginning in the US. PTC518 is a small chemical splicing modifier that may be taken orally and was created specifically to reduce huntingtin mRNA and protein. The underlying cause of HD is not currently being treated.<\/li>\n<li><strong>In January 2022, A new Phase II<\/strong> trial to assess tominersen in Huntington&#8217;s disease (HD) has been planned, according to an announcement by Ionis Pharmaceuticals and its partner Roche. Tominersen may benefit younger adult patients with reduced disease load, according to exploratory posthoc analysis conducted after treatment in the Phase III GENERATION HD1 study was stopped. It is necessary to confirm these findings in a randomised, placebo-controlled trial.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Huntington&rsquo;s Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Huntington&#8217;s disease is a genetically transmitted, neurodegenerative ailment that gradually impairs cognitive function and memory (dementia) as well as the development of uncontrollable motions of the hands, feet, face, and body.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free Sample PDF Report to know more about Huntington&rsquo;s Disease Pipeline Therapeutic Assessment-&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Huntington&rsquo;s Disease Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>TAK-686:<\/strong> Sangamo Therapeutics<\/li>\n<li><strong>Huntington&rsquo;s Disease therapy:<\/strong> Spark therapeutics<\/li>\n<li><strong>CKD-504:<\/strong> Chong Kun Dang Pharmaceutical<\/li>\n<li><strong>NP 001:<\/strong> Neuvivo<\/li>\n<li><strong>rAAV5-miHTT:<\/strong> UniQure Biopharma<\/li>\n<li><strong>WVE003:<\/strong> Wave Life Sciences<\/li>\n<li><strong>Branaplam:<\/strong> Novartis<\/li>\n<li><strong>SAGE-718:<\/strong> Sage Therapeutics<\/li>\n<li><strong>ANX005:<\/strong> Annexon<\/li>\n<li><strong>Valbenazine:<\/strong> Neurocrine Biosciences<\/li>\n<li><strong>Pridopidine:<\/strong> Prilenia Therapeutics<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Huntington&rsquo;s Disease Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">Huntington&rsquo;s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Huntington&rsquo;s Disease Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Huntington&rsquo;s Disease Products have been categorized under various Molecule types, such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Huntington&rsquo;s Disease Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Huntington&rsquo;s Disease Assessment by Product Type<\/li>\n<li>Huntington&rsquo;s Disease By Stage and Product Type<\/li>\n<li>Huntington&rsquo;s Disease Assessment by Route of Administration<\/li>\n<li>Huntington&rsquo;s Disease By Stage and Route of Administration<\/li>\n<li>Huntington&rsquo;s Disease Assessment by Molecule Type<\/li>\n<li>Huntington&rsquo;s Disease by Stage and Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&#8217;s Huntington&rsquo;s Disease Report covers around 50+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I)<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Further Huntington&rsquo;s Disease product details are provided in the report. Download the Huntington&rsquo;s Disease pipeline report to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/huntingtons-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">emerging Huntington&rsquo;s Disease therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies in the Huntington&rsquo;s Disease Therapeutics Market include:<\/strong><\/p>\n<p style=\"text-align: justify;\">Key companies developing therapies for Huntington&rsquo;s Disease are &#8211; <strong><em>Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, SAGE Therapeutics, PTC Therapeutics, WaVe life Sciences, Novartis, Neurimmune Therapeutics, SOLA Biosciences, UniQure Biopharma, Roche, Annexon, Inc., Azevan Pharmaceuticals, SOM Innovation Biotech SA, Asklepios BioPharmaceutical, Luye Pharma Group Ltd., BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG, Arvinas, Atalanta Therapeutics, Anima Biotech, and others.<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Huntington&rsquo;s Disease Pipeline Analysis:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Huntington&rsquo;s Disease pipeline report provides insights into&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Huntington&rsquo;s Disease with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Huntington&rsquo;s Disease Treatment.<\/li>\n<li>Huntington&rsquo;s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Huntington&rsquo;s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Huntington&rsquo;s Disease market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report to know more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/huntingtons-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Huntington&rsquo;s Disease drugs and therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Huntington&rsquo;s Disease Pipeline Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Introduction of disease-modifying drugs, further understanding in pathogenesis are some of the important factors that are fueling the Huntington&rsquo;s Disease Market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Huntington&rsquo;s Disease Pipeline Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>However, lesser approved therapies, stringent regulations and other factors are creating obstacles in the Huntington&rsquo;s Disease Market growth.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of Huntington&rsquo;s Disease Pipeline Drug Insight&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage: Global<\/strong><\/li>\n<li><strong>Key Huntington&rsquo;s Disease Companies:<\/strong> Sangamo Therapeutics, Spark therapeutics, Chong Kun Dang Pharmaceutical, Neuvivo, UniQure Biopharma, Wave Life Sciences, Novartis, Sage Therapeutics, Annexon, Neurocrine Biosciences, Prilenia Therapeutics, and others<\/li>\n<li><strong>Key Huntington&rsquo;s Disease Therapies:<\/strong> TAK-686, Huntington&rsquo;s Disease therapy, CKD-504, NP 001, rAAV5-miHTT, WVE003, Branaplam, SAGE-718, ANX005, Valbenazine, Pridopidine, and others<\/li>\n<li><strong>Huntington&rsquo;s Disease Therapeutic Assessment:<\/strong> Huntington&rsquo;s Disease current marketed and Huntington&rsquo;s Disease emerging therapies<\/li>\n<li><strong>Huntington&rsquo;s Disease Market Dynamics: Huntington&rsquo;s Disease market drivers and Huntington&rsquo;s Disease market barriers&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/huntingtons-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Huntington&rsquo;s Disease Pipeline Assessment and clinical trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Huntington&rsquo;s Disease Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Huntington&rsquo;s Disease Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Huntington&rsquo;s Disease Overview<\/p>\n<p style=\"text-align: justify;\">4. Huntington&rsquo;s Disease- Analytical Perspective In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">5. Huntington&rsquo;s Disease Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">6. Huntington&rsquo;s Disease Late Stage Products (Phase II\/III)<\/p>\n<p style=\"text-align: justify;\">7. Huntington&rsquo;s Disease Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">8. Huntington&rsquo;s Disease Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">9. Huntington&rsquo;s Disease Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Huntington&rsquo;s Disease Therapeutics Assessment<\/p>\n<p style=\"text-align: justify;\">11. Huntington&rsquo;s Disease Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">13. Huntington&rsquo;s Disease Key Companies<\/p>\n<p style=\"text-align: justify;\">14. Huntington&rsquo;s Disease Key Products<\/p>\n<p style=\"text-align: justify;\">15. Huntington&rsquo;s Disease Unmet Needs<\/p>\n<p style=\"text-align: justify;\">16 . Huntington&rsquo;s Disease Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">17. Huntington&rsquo;s Disease Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">18. Huntington&rsquo;s Disease Analyst Views<\/p>\n<p style=\"text-align: justify;\">19. Appendix<\/p>\n<p style=\"text-align: justify;\">20. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=huntingtons-disease-pipeline-and-clinical-trials-assessment-2023-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-sangamo-therapeutics-spark-therapeutics-chong-kun-dang-pharma\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 8774225362<br \/><strong>Address:<\/strong>27 Drydock Ave  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Boston<br \/><strong>State:<\/strong> MA<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=huntingtons-disease-pipeline-and-clinical-trials-assessment-2023-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-sangamo-therapeutics-spark-therapeutics-chong-kun-dang-pharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Las Vegas, Nevada, United States) As per DelveInsight\u2019s assessment, globally, Huntington\u2019s Disease pipeline constitutes 50+ key companies continuously working towards developing 50+ Huntington\u2019s Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/huntingtons-disease-pipeline-and-clinical-trials-assessment-2023-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-sangamo-therapeutics-spark-therapeutics-chong-kun-dang-pharma_665280.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-665280","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/665280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=665280"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/665280\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=665280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=665280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=665280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}